At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 14 enrolled
Drug / intervention
brolucuzumab 6 mg IVTbiological
Likely dose
brolucuzumab 6 mg IVTfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Open-Label, Multicenter, Phase IIIb Study to Collect Safety and Electrocardiogram Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Neovascular Age-Related Macular Degeneration
In Brief
A Phase 3 clinical trial evaluating brolucuzumab 6 mg IVT for Age-Related Macular Degeneration and 5 related conditions. Completed, enrolled 14 participants across 3 sites in 2 countries.
Detailed Summary
The purpose of this study was to collect ECG data after a single IVT injection of brolucizumab 6 mg in patients with neovascular age-related macular degeneration (nAMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration, Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJun 2019
Primary CompletionJul 2019
Study CompletionJul 2019
TodayJul 2026
First PostedMay 17, 2019
Enrollment StartJun 7, 2019
Primary CompletionJul 9, 2019
Study CompletionJul 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 7.1 years ago
Interventions
brolucuzumab 6 mg IVTbiological
Single intravitreal injection (IVT) of brolucizumab 6 mg